Lonsurf (Trifluridine/Tipiracil HCl) Patent Expiration, LOE Window & CMS Spending

Lonsurf (Trifluridine/Tipiracil HCl) by Taiho Oncology: FDA Orange Book core substance LOE 2034-06-17 (last listed 2037-02-03), 2 AB generics, $276.8M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTaiho Oncology
FDA Application & PathwayN207981 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2034-06-17
Last Listed Patent or Exclusivity Date2037-02-03
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$276.8M
2024 Medicare Part D Spend$225.9M
2024 Medicaid Spend$50.8M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel